Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Systemic lupus erythematosus--activity and outcome].

M Aringer1, J Smolen

  • 1Klinische Abt. für Rheumatologie, Universitätsklinik für Innere Medizin III, Wien. martin.aringer@meduniwien.ac.at

Zeitschrift Fur Rheumatologie
|February 28, 2006
PubMed
Summary

Systemic lupus erythematosus (SLE) presents complex organ challenges. New therapies require better outcome measures beyond severe endpoints like renal failure, necessitating improved surrogate markers for clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Management of systemic lupus erythematosus-Including secondary antiphospholipid syndrome, fertility and pregnancy : S3 guidelines of the German Society for Rheumatology and Clinical Immunology and the German Society for Neurology (DGN), German Society for Internal Medicine (DGIM), German Cardiac Society (DGK), Society for Thrombosis and Hemostasis Research (GTH), German Society for Hematology and Medical Oncology (DGHO), German Society for Pediatric and Adolescent Medicine (DGKJ), Society for Pediatric and Adolescent Rheumatology (GKJR), German Society for Nephrology (DGfN), German Society for Pneumology and Ventilation Medicine (DGP), German Rheumatism League National Association, Lupus Erythematosus Self-help Community, German Dermatological Society (DDG). Version: 1.2].

Zeitschrift fur Rheumatologie·2025
Same author

[Baricitinib for systemic lupus erythematosus].

Innere Medizin (Heidelberg, Germany)·2023
Same author

[Position paper of the German Society of Rheumatology e.V. (DGRh) regarding the situation of advanced training in the discipline of rheumatology in Germany].

Zeitschrift fur Rheumatologie·2023
Same author

Classification of systemic lupus erythematosus in children and adults.

Clinical immunology (Orlando, Fla.)·2021
Same author

[Development of quality standards for patients with rheumatoid arthritis for use in Germany].

Zeitschrift fur Rheumatologie·2021
Same author

[Rheumatology in German MD curricula].

Zeitschrift fur Rheumatologie·2020

Area of Science:

  • Rheumatology
  • Immunology
  • Nephrology

Background:

  • Systemic lupus erythematosus (SLE) exhibits diverse organ involvement, complicating clinical management.
  • Existing validated scores for SLE disease activity, damage, and quality of life are established.
  • Current therapeutic advancements necessitate refined outcome parameters for specific organ systems.

Purpose of the Study:

  • To address the challenge of defining and measuring treatment efficacy in SLE.
  • To evaluate the suitability of current outcome parameters for new SLE therapies.
  • To propose an optimized study design for assessing novel SLE treatment strategies.

Main Methods:

  • Review of existing validated scoring systems for SLE (e.g., SLEDAI, SLICC/ACR).
  • Analysis of outcome parameters used in clinical studies for proliferative lupus nephritis.

Related Experiment Videos

  • Evaluation of the reliability of surrogate markers for predicting long-term outcomes.

    • Main Results:

    • Validated scores exist for disease activity, damage, and quality of life in SLE.
    • Studies in lupus nephritis often use severe endpoints (renal failure, death), leading to long study durations.
    • No current surrogate markers reliably predict long-term outcomes in SLE.

    Conclusions:

    • Developing precise outcome parameters for specific organ systems is crucial for evaluating new SLE therapies.
    • A combined approach of shorter exploratory studies followed by longer definitive trials is recommended.
    • Improved surrogate markers are needed to accelerate the assessment of novel SLE treatment strategies.